[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100644746":3},{"organization":4,"armGroups":7,"interventions":37,"overallOfficials":52,"centralContacts":56,"locations":62,"responsibleParty":76,"collaborators":43,"id":78,"slug":43,"hasResults":79,"nctId":80,"briefTitle":81,"officialTitle":82,"acronym":43,"eligibilityCriteria":83,"healthyVolunteers":84,"sex":85,"minAge":86,"maxAge":87,"enrollmentInfo":88,"targetDuration":43,"studyType":91,"phases":92,"briefSummary":94,"conditions":95,"keywords":97,"overallStatus":65,"whyStopped":43,"lastUpdateSubmitDate":98,"lastUpdatePostDateStruct":99,"startDateStruct":102,"completionDateStruct":104,"leadSponsor":106,"locationsCount":107},{"fullName":5,"class":6},"AbbVie","INDUSTRY",[8,15,18,21,24,27,30,34],{"label":9,"type":10,"description":11,"interventionNames":12},"Part 1, Group 1: ABBV-313 or Placebo","EXPERIMENTAL","Participants will receive a single dose of ABBV-313 or Placebo",[13,14],"Drug: ABBV-313","Drug: Placebo",{"label":16,"type":10,"description":11,"interventionNames":17},"Part 1, Group 2: ABBV-313 or Placebo",[13,14],{"label":19,"type":10,"description":11,"interventionNames":20},"Part 1, Group 3: ABBV-313 or Placebo",[13,14],{"label":22,"type":10,"description":11,"interventionNames":23},"Part 1, Group 4: ABBV-313 or Placebo",[13,14],{"label":25,"type":10,"description":11,"interventionNames":26},"Part 1, Group 5: ABBV-313 or Placebo",[13,14],{"label":28,"type":10,"description":11,"interventionNames":29},"Part 1, Group 6: ABBV-313 or Placebo",[13,14],{"label":31,"type":10,"description":32,"interventionNames":33},"Part 2, Group 7: ABBV-313 or Placebo","Participants will receive multiple doses of ABBV-313 or Placebo",[13,14],{"label":35,"type":10,"description":32,"interventionNames":36},"Part 2, Group 8: ABBV-313 or Placebo",[13,14],[38,44,47,50],{"type":39,"name":40,"description":41,"armGroupLabels":42,"otherNames":43},"DRUG","ABBV-313","Injection",[9,16,25,31,35],null,{"type":39,"name":45,"description":41,"armGroupLabels":46,"otherNames":43},"Placebo",[9,16,25,31,35],{"type":39,"name":40,"description":48,"armGroupLabels":49,"otherNames":43},"Infusion",[19,22,28],{"type":39,"name":45,"description":48,"armGroupLabels":51,"otherNames":43},[19,22,28],[53],{"name":54,"affiliation":5,"role":55},"ABBVIE INC.","STUDY_DIRECTOR",[57],{"name":58,"role":59,"phone":60,"phoneExt":43,"email":61},"ABBVIE CALL CENTER","CONTACT","844-663-3742","abbvieclinicaltrials@abbvie.com",[63],{"facility":64,"status":65,"city":66,"state":67,"zip":68,"country":69,"cosmosGeoPoint":70,"geoPoint":75,"contacts":43},"Acpru \u002FId# 283495","RECRUITING","Grayslake","Illinois","60030","United States",{"type":71,"coordinates":72},"Point",[73,74],-88.04175,42.34447,{"lat":74,"lon":73},{"type":77,"investigatorFullName":43,"investigatorTitle":43,"investigatorAffiliation":43,"oldNameTitle":43,"oldOrganization":43},"SPONSOR","100644746",false,"NCT07673120","A Study to Assess Safety, Tolerability, and How Single and Multiple Injections or Infusions of ABBV-313 Affects the Body of Adult Participants","A Phase 1, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Single Ascending Doses and Multiple Doses of ABBV-313","Inclusion Criteria:\n\n* BMI is \\>= 18.0 to \\\u003C= 29.9 kg\u002Fm2 after rounding to the tenths decimal at Screening. BMI is calculated as weight in kg divided by the square of height measured in meters.\n* A condition of general good health, based upon the results of a medical history, physical examination, vital signs, laboratory profile and a 12-lead ECG.\n\nExclusion Criteria:\n\n* History of any clinically significant sensitivity or allergy to any medication or food.\n* History of any clinically significant illness\u002Finfection\u002Fmajor febrile illness, hospitalization, or any surgical procedure within 30 days prior to the first dose of study treatment.\n* Participant has prior exposure to ABBV-313 within the past 300 days.",true,"ALL","18 Years","55 Years",{"count":89,"type":90},64,"ESTIMATED","INTERVENTIONAL",[93],"PHASE1","The objective of this study is to assess the safety, tolerability, pharmacokinetics, and immunogenicity of single and multiple doses of ABBV-313 in healthy adult participants.",[96],"Healthy Volunteers",[96,40],"2026-06-23",{"date":100,"type":101},"2026-06-29","ACTUAL",{"date":103,"type":90},"2026-06-22",{"date":105,"type":90},"2028-02",{"name":5,"class":6},1]